Value of Von Willebrand Factor in Portal Hypertension

Von Willebrand Factor As Non-Invasive Predictor Of Clinically Significant Portal Hypertension And Mortality In Patients With Liver Cirrhosis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01358123

Enrollment

300

Registered

2011-05-23

Start date

2006-09-30

Completion date

2016-06-30

Last updated

2015-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cirrhosis, Portal Hypertension

Keywords

liver cirrhosis, portal hypertension, survival, von willebrand factor, hepatic venous pressure gradient

Brief summary

In patients with liver cirrhosis elevated levels of von Willebrand factor antigen (vWF-Ag) are found frequently but the clinical significance is unclear. vWF-Ag plays an important role in primary haemostasis and development of thrombotic vascular obliteration is discussed as a possible mechanism leading to portal hypertension. Invasive measurement of hepatic venous pressure gradient (HVPG) is the current gold standard for the diagnosis of portal hypertension. The investigators hypothesize that vWF-Ag levels in plasma may correlate with portal pressure and predict clinically significant portal hypertension (CSPH, HVPG \>=10mmHg) and its complications.

Detailed description

Patients with alcoholic, viral (chronic hepatitis C), and cryptogenic liver cirrhosis are included. Portal hemodynamics are assessed by HVPG measurement, vWF-Ag levels were measured by ELISA. Results will be compared. 3 and 6 months mortality will be recorded.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 98 Years

Healthy volunteers

Inclusion criteria

* Liver cirrhosis

Exclusion criteria

* no HVPG measurement

Design outcomes

Primary

Measure	Time frame	Description
von Willebrand Factor Ag Level	at first visit (HVPG Measurement) (day 1)	von Willebrand Factor Antigen Levels are measured via ELISA and compared /corrlated to Hepatic Venous Pressure Gradient (HVPG). von Willebrand Factor Antigen levels are drawn and analyzed at the day of HVPG measurement. No follow up measurements will be performed, survival will be measured as secondary outcome parameter

Secondary

Measure	Time frame	Description
Overall Mortality	3 Months	Survival of Patients after index measurement of von Willebrand Factor and HVPG

Countries

Austria

Contacts

Primary ContactArnulf Ferlitsch, MD

arnulf.ferlitsch@meduniwien.ac.at+43140400

Outcome results